CurrentPremera BluecrossPolicy N/A

Pharmacologic Management of Neuropathic Pain, Fibromyalgia, and Seizure Disorders (pregabalin, gabapentin, capsaicin patch, milnacipran, duloxetine)

Defines medical necessity and prior authorization documentation requirements for Lyrica/pregabalin, Lyrica CR/pregabalin ER, Neurontin/gabapentin, Qutenza/capsaicin patch, Savella/milnacipran, and duloxetine for indications including neuropathic pain, diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, seizure disorders, and generalized anxiety disorder; specifies benefit management (pharmacy vs medical), length of approval, and required trials of generic agents.

Policy Summary

PayerPremera Bluecross

PolicyPharmacologic Management of Neuropathic Pain, Fibromyalgia, and Seizure Disorders (pregabalin, gabapentin, capsaicin patch, milnacipran, duloxetine)

Policy CodePolicy N/A

Change TypeCriteria additions & clarifications

Effective DateJuly 4, 2024 (Qutenza addition)

Next Review Date

Key ActionProvide chart notes/medical records with prior authorization to demonstrate that medical necessity criteria are met, including diagnosis, relevant physical evaluation and medication history.

POLICY UPDATE CHANGES

Added coverage criteria for Qutenza (capsaicin) for treatment of postherpetic neuralgia and diabetic peripheral neuropathy effective July 4, 2024.

Updated coverage criteria to specify prerequisite medications tried must be generic dosage forms (Interim Review approved 01/01/25).

Clarified that non-formulary exception review authorizations for all drugs may be approved up to 12 months (approved 02/24/2025).

Added coverage for Neurontin (gabapentin) for treatment of neuropathic pain and seizure disorders (effective 09/01/25 noted in history).

5Drugs with specific coverage criteria listed

>=1

Minimum prior medication trials required (varies)

12Maximum authorization length (non-formulary/other reviews)

Coverage summary

This policy defines medical necessity and prior authorization requirements for pharmacologic treatment of neuropathic pain, fibromyalgia, seizure disorders, and related indications for specific branded and generic agents (including pregabalin/Lyrica and Lyrica CR, gabapentin/Neurontin, duloxetine/Cymbalta, milnacipran/Savella, and the capsaicin 8% patch/Qutenza). Benefit management is specified: Qutenza is managed under the medical benefit (HCPCS J7336) while the other listed drugs are managed under the pharmacy benefit. Authorization length and administrative rules are noted (non-formulary/other reviews may be approved up to 12 months). The policy takes a mixed coverage stance — it lists specific indications and required prior trials for medical necessity and declares uses not outlined as not medically necessary.

Age thresholds and authorization length

Lyrica (pregabalin) — neuropathic pain & fibromyalgia age>= 18 years

Lyrica (pregabalin) — seizure disorder age>= 1 month

Neurontin (gabapentin) — seizure disorder age>= 3 years

Savella (milnacipran) — fibromyalgia age>= 18 years

Maximum authorization length (non-formulary/other reviews)Up to 12 months

NoteAges stated are based on FDA prescribing information

Initial therapy / medical necessity criteria

Initial therapy coverage and exclusions for Lyrica, Lyrica CR, Neurontin, Qutenza, and Savella

Initial therapy coverage criteria for the listed drugs and indications. Each top-level node encodes the policy's AND/OR logic and prerequisite generic medication trials as stated in the policy.

Lyrica (pregabalin) - neuropathic pain

ALL of the following
- Age: The individual is aged 18 years or older
- Prior trial: gabapentin: Has tried and had an inadequate response or intolerance to generic gabapentin
- Prior trial: 1 of the following generic medications

Prior authorization and documentation requirements

Prior Authorization

Prior authorization required with documentation

Prior authorization review requires submission of documentation demonstrating that the medical necessity criteria are met. Provide chart notes or medical records that support the request.

diagnosis
relevant physical evaluation
medication history

Prior Authorization

Benefit management

Qutenza (capsaicin) is managed under the medical benefit (HCPCS code J7336). All other drugs listed in this policy are managed under the pharmacy benefit. Non‑formulary exception reviews and other reviews for drugs in this policy may be approved for up to 12 months.

Applicable codes

Medical benefit HCPCS for QutenzaHCPCSCovered

J7336

Capsaicin 8% patch (Qutenza), per sq cm

Evidence and trial highlights

>=30%Pregabalin fibromyalgia responders (>=30% pain reduction); benefit up to 450 mg/day

60-120 mgDuloxetine DPN: significant decrease in 24-hour average pain at 60-120 mg/day (Phase III trials)

2 trialsQutenza: two 12-week RCTs in postherpetic neuralgia with single 60-minute application

Evidence summarized in the policy includes pivotal randomized trials and prescribing information for the agents covered. Duloxetine (Cymbalta) has Phase III trials in diabetic peripheral neuropathy showing decreased 24-hour average pain at doses of 60–120 mg/day with responder definitions of a ≥30% reduction in baseline pain used in trials; duloxetine also showed efficacy in short-term fibromyalgia trials (12-week and 6-month studies) at doses up to 120 mg/day though 60 mg/day is commonly cited as effective. Pregabalin (Lyrica) demonstrated modest efficacy in neuropathic pain and is approved for fibromyalgia; fibromyalgia trials defined responders as ≥30% pain reduction and benefit was observed up to 450 mg/day (studies evaluated doses to 450 mg/day and higher in some trials). Qutenza (capsaicin 8% patch) efficacy was established in two 12-week randomized, controlled trials in postherpetic neuralgia using a single 60-minute application and showed greater pain reduction versus a low-dose active control. Milnacipran (Savella) has randomized trials showing superiority to placebo in fibromyalgia at commonly studied doses, but longer-term data are less consistent and safety monitoring (blood pressure, heart rate, LFTs) is noted. Gabapentin evidence includes trials showing reduced neuropathic pain with doses up to 3600 mg/day used in some studies and long titration periods. These items reflect the guideline and trial evidence cited in the policy and the FDA labeling referenced for each drug.

Background and definitions

This policy covers pharmacologic management of neuropathic pain, fibromyalgia, and seizure disorders and specifies coverage criteria for pregabalin (Lyrica and Lyrica CR), gabapentin (Neurontin), duloxetine (Cymbalta), milnacipran (Savella), and the capsaicin 8% patch (Qutenza). It documents that Qutenza is managed under the medical benefit (HCPCS J7336) while the other agents are managed under the pharmacy benefit, and it records multiple policy updates and annual reviews spanning 2005–2025 including additions and clarifications effective July 4, 2024; interim updates in 2024–2025; and other history entries back to 2005.

Inadequate response or intolerance: clinical judgment that a prior medication trial failed to produce sufficient therapeutic benefit or produced unacceptable side effects, as documented in the medical record.

Policy revision history

2024-07-04added

Added coverage criteria for Qutenza (capsaicin) for treatment of postherpetic neuralgia and diabetic peripheral neuropathy; Qutenza is managed under the medical benefit and coded as HCPCS J7336 (capsaicin 8% patch, per sq cm).

2025-01-01revised

Updated coverage criteria to specify that prerequisite medications tried must be generic dosage forms and clarified that medications listed are subject to the product's FDA dosage and administration prescribing information.

2025-02-24clarified

Clarified that non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months (administrative clarification to length of approval).

Policy Summary

PayerPremera Bluecross

PolicyPharmacologic Management of Neuropathic Pain, Fibromyalgia, and Seizure Disorders (pregabalin, gabapentin, capsaicin patch, milnacipran, duloxetine)

Policy CodePolicy N/A

Change TypeCriteria additions & clarifications

Effective DateJuly 4, 2024 (Qutenza addition)

Next Review Date

On This Page

TCA: tricyclic antidepressant (e.g., amitriptyline)

SNRI: an SNRI (e.g., duloxetine, venlafaxine)

Prior trial: pregabalin: Has tried and had an inadequate response or intolerance to generic pregabalin or generic pregabalin extended-release

Lyrica (pregabalin) - seizure disorder

ALL of the following
- Age: The individual is aged 1 month or older
- Prior trial: pregabalin: Has tried and had an inadequate response or intolerance to generic pregabalin or generic pregabalin extended-release

Lyrica (pregabalin) - fibromyalgia

ALL of the following
- Age: The individual is aged 18 years or older
- Prior trial: gabapentin: Has tried and had an inadequate response or intolerance to generic gabapentin
- Prior trial: 1 of the following generic medications
  - TCA: tricyclic antidepressant (e.g., amitriptyline)
  - SNRI: an SNRI (e.g., duloxetine, venlafaxine)
- Prior trial: pregabalin: Has tried and had an inadequate response or intolerance to generic pregabalin or generic pregabalin extended-release

Lyrica (pregabalin) - generalized anxiety disorder

ALL of the following
- Age: The individual is aged 18 years or older
- Prior trial: SSRI: Has tried and had an inadequate response or intolerance to a generic SSRI (e.g., citalopram, fluoxetine)
- Prior trial: 1 of the following generic medications
  - Benzodiazepines (e.g., alprazolam, clonazepam)
  - Buspirone
  - Venlafaxine
  - Hydroxyzine
  - Duloxetine

Lyrica CR (pregabalin ER) - diabetic peripheral neuropathy or postherpetic neuralgia

ALL of the following
- Age: The individual is aged 18 years or older
- Prior trial: gabapentin: Has tried and had an inadequate response or intolerance to generic gabapentin
- Prior trial: 1 of the following generic medications
  - TCA: tricyclic antidepressant (e.g., amitriptyline)
  - SNRI: an SNRI (e.g., duloxetine, venlafaxine)
- Prior trial: pregabalin: Has tried and had an inadequate response or intolerance to generic pregabalin or generic pregabalin extended-release

Neurontin (gabapentin) - neuropathic pain

ALL of the following
- Age: The individual is 18 years or older
- Prior trial: gabapentin: Has tried and had an inadequate response or intolerance to generic gabapentin
- Prior trial: 1 of the following generic medications
  - TCA: tricyclic antidepressant (e.g., amitriptyline)
  - SNRI: an SNRI (e.g., duloxetine, venlafaxine, desvenlafaxine)
- Prior trial: pregabalin: Has tried and had an inadequate response or intolerance to generic pregabalin or generic pregabalin extended-release

Neurontin (gabapentin) - seizure disorder

ALL of the following
- Age: The individual is aged 3 years or older
- Prior trial: gabapentin: Has tried and had an inadequate response or intolerance to generic gabapentin

Qutenza (capsaicin 8% patch) - diabetic peripheral neuropathy or postherpetic neuralgia

ALL of the following
- Age: The individual is aged 18 years or older
- Prior trial: gabapentin: Has tried and had an inadequate response or intolerance to generic gabapentin
- Prior trial: 1 of the following generic medications
  - TCA: tricyclic antidepressant (e.g., amitriptyline)
  - SNRI: an SNRI (e.g., duloxetine, venlafaxine, desvenlafaxine)

Savella (milnacipran) - fibromyalgia

ALL of the following
- Age: The individual is 18 years or older
- Prior trial: gabapentin: Has tried and had an inadequate response or intolerance to generic gabapentin
- Prior trials: 2 of the following generic medications
  - TCA: tricyclic antidepressant (e.g., amitriptyline)
  - SNRI: an SNRI (e.g., duloxetine, venlafaxine)
  - Cyclobenzaprine
  - Tramadol

General rule - Not Medically Necessary / Investigational

Not medically necessary uses: All other uses of Lyrica, Lyrica CR, Neurontin, Qutenza, and Savella for conditions not outlined in this policy are considered not medically necessary
FDA dosing: These drugs are subject to the product's FDA dosage and administration prescribing information

Documentation Required

Required record elements

Medical records submitted for prior authorization must include office visit notes that document the diagnosis, relevant physical evaluation, and the medication history to support that coverage criteria are met.

office visit notes
diagnosis
relevant physical evaluation
medication history

Billing Rule

Follow FDA dosing/administration

Medications covered by this policy are subject to the product's FDA dosage and administration (prescribing) information; follow the FDA prescribing information for dosing and administration.

2025-09-01addedLatest

Added coverage for Neurontin (gabapentin) for treatment of neuropathic pain and seizure disorders (history entry notes effective date).